PWE-132 Therapeutic outcomes following endotherapy for refractory gastroparesis

IntroductionThe relative merits of endotherapy for refractory gastroparesis remain unclear. We assessed the symptomatic response of patients undergoing non-surgical pyloric intervention at a specialist tertiary centre.Methods57 patients (21 male, mean age 47, 16–81) with medical refractory gastroparesis (29 idiopathic, 5 diabetic, 23 post-gastric transposition) underwent 117 endoscopic treatments from Sep 2013-Sep 2017: either 100IU units of Botox injected into 4 quadrants of the pylorus (n≥66), balloon dilatation to 15–20 mm (EBD, n≥13) or combination therapy (n≥38). Patients with gastric malignancy, pyloric surgery or no follow-up were excluded. Symptoms were assessed immediately prior to each procedure and at first follow up using a retrospective scoring system based on the presence (1 point) or absence (0 points) of Vomiting, Nausea, Bloating or Early satiety. This formulated a composite symptom score (SS) out of 4; positive response was defined by improvement in SS of at least 1. Statistical analysis was performed using Wilcoxon Signed-Rank Test and Fischer’s Test.ResultsThere were no immediate or late complications. Mean symptom score (SS) improved per-patient from 2.1 points at baseline to 1.2 post initial endotherapy(p